LBRX

LB Pharmaceuticals Inc Common Stock

LBRX

Market cap $322M

Overview Fund Activity

16.02 USD

+0.24

1.52%

At close Updated Sep 17, 10:00 AM EDT

1 day

1.52%

5 days

-15.68%

1 month

-7.4%

3 months

-7.4%

6 months

-7.4%

Year to date

-7.4%

1 year

-7.4%

5 years

-7.4%

10 years

-7.4%

About: LB Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing novel therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. It is building a pipeline that leverages the broad therapeutic potential of its lead product candidate, LB-102, which the company believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is a new chemical entity and a methylated derivative of amisulpride, a second-generation antipsychotic drug approved in over 50 countries.

Healthcare Biotechnology

–

Funds holding %

of 7,463 funds

–

Analysts bullish %

Financial journalist opinion

Based on 5 articles about LBRX published over the past 30 days

LB Pharma valued at $382 million as shares jump in New York debut

LB Pharmaceuticals' shares rose 27% in their Nasdaq debut on Thursday, giving the biotech firm a valuation of $381.9 million and opening the door for companies looking to tap the public markets before 2026.

LB Pharma valued at $382 million as shares jump in New York debut

LB Pharmaceuticals raises $285 million in US IPO

LB Pharmaceuticals raised $285 million in its U.S. initial public offering, the biotech firm said on Wednesday, marking the first sizable biotech IPO since February.

LB Pharmaceuticals raises $285 million in US IPO

LB Pharmaceuticals Announces Pricing of its Upsized Initial Public Offering

NEW YORK, Sept. 10, 2025 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals”) today announced the pricing of its upsized initial public offering of 19,000,000 shares of its common stock at a public offering price of $15.00 per share. The aggregate gross proceeds to LB Pharmaceuticals from the offering are expected to be $285.0 million before deducting underwriting discounts and commissions and other offering expenses payable by LB Pharmaceuticals. In addition, LB Pharmaceuticals has granted the underwriters a 30-day option to purchase up to an additional 2,850,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions.

LB Pharmaceuticals Announces Pricing of its Upsized Initial Public Offering

LB Pharmaceuticals eyes $322 million valuation in biotech IPO amid sector drought

Cash-strapped drug developer LB Pharmaceuticals said on Monday it was aiming for a valuation of up to $321.6 million in its New York initial public offering, potentially setting up the first sizable U.S. biotech flotation in months.

LB Pharmaceuticals eyes $322 million valuation in biotech IPO amid sector drought

LB Pharmaceuticals Launches $100 Million IPO Effort

LB Pharmaceuticals Inc. is preparing a $100 million IPO to fund Phase 3 trials for its schizophrenia drug, LB-102, after positive Phase 2 results. The company targets a large, growing schizophrenia drug market but faces significant competition from major pharmaceutical firms and startups. IPO proceeds will advance LB-102 through Phase 3 trials and potentially expand indications to bipolar depression, with additional funds for general corporate purposes.

LB Pharmaceuticals Launches $100 Million IPO Effort

See News Rankings

Charts implemented using Lightweight Charts™